Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 31, Issue 3, 2013, Pages 256-284

  Iqbal, Almas ^a   Ahmad, Iqra ^a   Khalid, Mohammad Hassan ^a   Nawaz, Muhammad Sulaman ^a   Gan, Siew Hua ^b   Kamal, Mohammad A ^c  

^a Department of Electrical Computer Engineering   (Pakistan)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

bioinformatics; blood brain barrier; central nervous system; computational; nanoneuroprotection; Nanoparticles; neurodegenerative diseases; neurotoxicity; oxidative stress; QSAR

Indexed keywords

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; COMPUTATIONAL; NANONEUROPROTECTION; NEUROTOXICITY; QSAR;

BIOINFORMATICS; BIOLOGY; BLOOD; COMPUTATIONAL CHEMISTRY; DRUG DELIVERY; GENE EXPRESSION; NANOPARTICLES; NEURODEGENERATIVE DISEASES; NEUROPHYSIOLOGY; OXIDATIVE STRESS; PROTEINS; TOXICITY; TUMORS;

PATHOLOGY;

ALBUMIN; ALKALOID; ANTIOXIDANT; CERIUM OXIDE; DOPAMINE; IMMUNOGLOBULIN G; LIPID; LIPOSOME; METAL ION; MULTI WALLED NANOTUBE; NANOPARTICLE; NEUROPROTECTIVE AGENT; NITROSOUREA; POLYPHENOL; PRODRUG; REACTIVE OXYGEN METABOLITE; SILVER NANOPARTICLE; SINGLE WALLED NANOTUBE; SUPERPARAMAGNETIC IRON OXIDE; TETRAETHYLLEAD; TITANIUM DIOXIDE;

ACTION POTENTIAL; ACTIVE TRANSPORT; ADSORPTION; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; DRUG DELIVERY DEVICE; ELECTROSTIMULATION; ENDOCYTOSIS; ENVIRONMENTAL EXPOSURE; EXHAUST GAS; GENE EXPRESSION; HEALTH HAZARD; HUMAN; HUNTINGTON CHOREA; LIPID RAFT; LIPOPHILICITY; NANOBIOTECHNOLOGY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARTICLE SIZE; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SYNAPTIC TRANSMISSION;

ANIMALS; BIOLOGICAL TRANSPORT; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOPARTICLES; RATS;

EID: 84884536019     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590501.2013.829706     Document Type: Article

References (143)

1. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005;113:823-839.
2. Win-Shwe TT, Fujimaki H. Nanoparticles and neurotoxicity. Int J Mol Sci. 2011;12:6267-6268.
3. Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: Nanotoxicology and beyond. Toxicol Sci. 2011;120:109-129.
4. Begley DJ. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol. 1996;48:136-146.
5. Schlosshauer B, Steuer H. Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Curr Med Chem. 2002;2:175-186.
6. Graeme R. CNS cancers. Burger's Medicinal Chemistry, Drug Discovery and Development. 2010:223-294.
7. Cornford EM, Braun LD, Oldendorf WH, Hill MA. Comparison of lipidmediated blood-brain barrier penetrability in neonates and adults. Am J Physiol. 1982;243:161-168.
8. Xia XR, Monteiro-Riviere NA, Mathur S, Song X, Xiao L, Oldenberg SJ, Fadeel B, Riviere JE. Mapping the surface adsorption forces of nanomaterials in biological systems. ACS Nano. 2011;5:9074-9081.
9. Nel AE, Madler L, Velegol D, Xia T,Hoek EM, Somasundaran P, Klaessig F, Castranova V, Thompson M. Understanding biophysicochemical interactions at the nanobio interface. Nat Mater. 2009;8:543-557.
10. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine. 2007;2:789-803.
11. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci. 2007;134:167-174.
12. Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol. 2000;20:231-253.
13. Thorne RG, Frey WH 2nd. Delivery of neurotropic factors to the central nervous system: Pharmacokinetic consideration. Clin Pharmacokinet. 2001;40:907-946.
14. Filmore D. Breaching the blood-brain barrier. Modern Drug Discov. 2002;5:22-24.
15. Bodor N, Kaminski JJ. Prodrugs and site-specific chemical delivery systems. Annu Rep Med Chem. 1987;22:303-313.
16. Marcel Gielen, ER. Metallotherapeutic drugs and metal-based diagnostic agents: The use of metals in medicine. John Wiley & Sons Ltd: England, 2005; p.693.
17. Goka TJ, Stevenson RE, Hefferan PM, Howell RR. Menkes disease: A biochemical abnormality in cultured human fibroblast. Proc Natl Acad Sci USA. 1976;73:604-606.
18. Lutsenko S, Bartee MY, Linz R, Ralle M. Copper transport in human cells: The role of Cu-transporting ATPases. Biochem Soc Trans. 2008;36:1233-1238.
19. Milman N, Pedersen P, Steig TA, Melsen GV. Frequencies of the hereditary hemochromatosis allele in different populations. Comparison of previous phenotypic methods and novel genotypic methods. Int J Hematol. 2003;77:48-54.
20. Krishnan A, Dujardin E, Ebbesen TW, Yianilos PN, Treacy MMJ. Young's modulus of single-walled nanotubes. Physical Review B. 1998;58:14013-14019.
21. Lijima S. Helical microtubules of graphitic carbon. Nature. 1991;354:56-58.
22. Robichaud CO, Tanzil D, Weilenmann U, Wiesner MR. Relative risk analysis of several manufactured nanomaterials: An insurance industry context. Environ Sci Technol. 2005;39:8985-8994.
23. Yang Z, Liu ZW, Allaker RP, Reip P, Oxford J, Ahmad Z, Ren G. A review of nanoparticle functionality and toxicity on the central nervous system. J R Soc Interface. 2010;7:411-422.
24. Donaldson K, Stone V, Clouter A, Renwick L, MacNee W. Ultrafine particles. Occup Environ Med. 2001;58:211-216.
25. Donaldson K, Stone V, Seaton A, MacNee W. Ambient particle inhalation and the cardiovascular system: Potential mechanisms. Environ Health Perspect. 2001;109:523-527.
26. Morimoto Y, Kobayashi N, Shinohara N, Myojo T, Tanaka I, Nakanishi J. Hazard assessments of manufactured nanomaterials. J Occup Health. 2010;52:325-334.
27. Farrer LA. Intercontinental epidemiology of Alzheimer disease: A global approach to bad gene hunting. JAMA. 2001;285:796-798.
28. Alzheimer's Association. 2012 Alzheimer's disease facts and figures; Alzheimers Demeat. 2012; 8(2):131-168.
29. Parveen Z, Nawaz MS, Shakil S, Grieg NH, Kamal MA. Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl] carbamic acid with tyrosine hydroxylase. CNS & Neurological Disorders-Drug Targets. 2012;11:463-468.
30. Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem. 1999;32:595-603.
31. Orringer D, Koo YE, Chen T, Kopelman R, Sagher O, Philbert MA. Small solutions for big problems: The application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther. 2009;85:531-534.
32. Burch WM. Passage of inhaled particles into the blood circulation in humans. Circulation. 2002;106;141-142.
33. Takenaka S, Karg E, Roth C, Schulz H, Ziesenis A, Heinzmann U, Schramel P, Heyder J. Pulmonary and systemic distribution of inhaled ultrafine silver particles in rats. Environ Health Perspect. 2001;109: 547-551.
34. Veronesi B, Makwana O, Pooler M, Chen LC. Effects of subchronic exposures to concentrated ambient particles. VII. Degeneration of dopaminergic neurons in Apo E-/-mice. Inhal Toxicol. 2005;17:235-241.
35. Block ML, Wu X, Pei Z, Li G, Wang T, Qin L, Wilson B, Yang J, Hong JS, Veronesi B. Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: The role of microglia, phagocytosis, and NADPH oxidase. FASEB J. 2004;18:1618-1620.
36. Brown D, Stone V, Findlay P, MacNee W, Donaldson K. Increased inflammation and intracellular calcium caused by ultrafine carbon black is independent of transition metals or other soluble components. Occup Environ Med. 2000;57:685-691.
37. Yamakoshi Y, Umezawa N, Ryu A, Arakane K, Miyata N, Goda Y, Masumizu T, Nagano T. Active oxygen species generated from photoexcited fullerene (C60) as potential medicines: O2 versus 1O2. J Am Chem Soc. 2003;125:1283-1289.
38. Shimizu M, Tainaka H, Oba T, Mizuo K, Umezawa M, Takeda K. Maternal exposure to nanoparticulate titanium dioxide during the prenatal period alters gene expression related to brain development in the mouse. Part Fibre Toxicol. 2009;6:1-8.
39. Takada Y, Vistiea DT, Greig NH, Purdon D, Rapoport SI, Smith QR. Rapid highaffinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Research. 1992;52:2191-2196.
40. Buzea C, Pacheco Blandino II, Robbie K. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases. 2007;2:MR17-MR172.
41. Suckling AJ The blood-brain barrier in health and disease, (D. A. Wiseman, Ed) Ellis Horwood health science series. England; 1986:132-147.
42. Abbott, NJ. Physiology and pharmacology of the blood-brain barrier. vol. 103. Springer-Verlag; Berlin, Heidelberg. 1992.
43. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Rev. 2001;38:140-148.
44. Brownless J, Williams CH. Peptidases, peptides and the mammalian blood-brain barrier. J Neuroche. 1993;60:1089-1096.
45. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides. 2001;22:2329-2343.
46. Nabeshima S, Reese TS, Landis DM, Brightman MW. Junctions in the meninges and marginal glia. J Comp Neurol. 1975;164:127-169.
47. Pardridge WM. Recent advances in blood brain-barrier transport. Annu Rev Pharmacol Toxicol. 1988;28:25-39.
48. Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: Focus on brain lymphoma. Clin Pharmacokinet. 2002;41:171-186.
49. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: A review. J Pharm Pharm Sci. 2003;6(2):252-273.
50. Colvin VL. The potential environmental impact of engineered nanomaterials. Nat Biotech. 2003;21:1166-1170.
51. Lynch I, Dawson KA, Linse S. Detecting cryptic epitopes created by nanoparticles. Sci STKE. 2006;327:14.
52. Shemetov AA, Nabiev I, Sokhanova A. Molecular interaction of proteins and peptides with nanoparticles. ACS Nano. 2012;6:4585-4602.
53. Smita S, Gupta SK, Bartonova A, Dusinska M, Gutleb AC, Rahman Q. Nanoparticles in the environment: Assessment using the causal diagram approach. Environ Health. 2012;11:1-13.
54. De Jong WH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine. 2008;3:133-149.
55. Cedervall T, Lynch I, Berggard SLT, Thulin E, Nilsson H, Dawson KA, Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. PNAS. 2007;104:2050-2055.
56. Montes-Burgos I, Walczyk D, Hole P, Smith J, Lynch I, Dawson K. Characterisation of nanoparticle size and state prior to nanotoxicological studies. J Nanopart Res. 2010;12:47-53.
57. Kendall M, Ding P, Kendall K. Particle and nanoparticle interactions with fibrinogen: The importance of aggregation in nanotoxicology. Nanotoxicology. 2011;5:55-65.
58. Lynch I, Dawson KA. Protein-Nanoparticle interactions. Nano Today. 2008;3: 40-47.
59. Patil S, Sandberg A, Heckert E, Self W, Seal S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28:4600-4607.
60. Weissleder R, Cheng H, Bogdanova A, Bogdanov Jr A. Magnetically-labeled cells can be detected by MR imaging. J Magn Reson Imaging. 1997;7:258-263.
61. Corot C, Petry KG, Trivedi R, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Investig Radio. 2004;39:619-625.
62. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415-422.
63. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: Mechanisms and comparison of ferumoxides and ferumoxtran-10. Investig Radiol. 2004;39:56-63.
64. Daldrup-Link HE, Rudelius M, Piontek G, et al. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology. 2005;234:197-205.
65. Lockman PR, Oyewumi MO, Koziara JM, Roder K, Mumper RJ, Allen DD. Brain uptake of thiamine-coated Nanoparticles. J Control Rel. 2003;93:271-282.
66. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol. 2004;4:484-488.
67. Muller RH, Keck CM. Drug delivery to the brain: Realization by novel drug carriers. J Nanosci Nanotechnol. 2004;4:471-483.
68. Obersdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C. Translocation of inhaled ultrafine particles to the brain. Inhalation Toxicol. 2004;16:437-445.
69. Kandimalla KK, Donovan MD. Carrier mediated transport of chlorphe chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: Implications on noseto-brain transport. J Pharm Sci. 2005;94:613-624.
70. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles-Potential implications for drug delivery. J Nanosci Nanotechno. 2005;4:521-531.
71. Hoet PHM, Bruske-Hohlfeld I, Salata OV. Nanoparticles-known and unknown health risks. J Nanobiotechnoogyl. 2004;2:12.
72. Au C, Mutkus L, Dobson A, Riffle J, Lalli J, Aschner M. Effects of nanoparticles on the adhesion and cell viability on astrocytes. Biol Trace Elem Res. 2007;120:248-256.
73. Cengelli F, Maysinger D, Tschudi-Monnet F, Montet X, Corot C, Petri-Fink A, Hofmann H, Juillerat-Jeanneret L. Interaction of Functionalized Superparamagnetic Iron Oxide nanoparticles with brain structures. J Pharmacol Exp Ther. 2006;318:108-116.
74. Engelhardt B. Development of the blood-brain barrier. Cell and Tissue Research. 2003;314:119-129.
75. Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target. 2004;12:635-641.
76. Keselowsky BG, Collard DM, Garć?a AJ. Surface chemistry modulates focal adhesion composition and signaling through changes in integrin binding. Biomaterials. 2004;25:5947-5954.
77. Mahmoudi ML, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. Protein-nanoparticle interactions: Opportunities and challenges. Chem Rev. 2011;111:5610-5637.
78. Xu M, Li J, Iwai H, Mei Q, Fujita D, Su H, Chen H, Hanagata N. Formation of nano-bio-complex as nanomaterials dispersed in a biological solution for understanding nanobiological interactions. Scientific Reports. 2012;2:406.
79. Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Targeting. 2001;9:267-279.
80. Oberdorster E. Manufactured nanomaterials (fullerenes,C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect. 2004;112:1058-1062.
81. Panyala NR, Pena-Mendez EM, Havel J. Silver or silver nanoparticles: A hazardous threat to the environment and human health. J Appl Biomed. 2008;6:117-129.
82. Rungby J, Danscher G. Localization of exogenous silver in brain and spinal cord of silver exposed rats. Acta Neuropathol. 1983;60:92-98.
83. Sarin H, Kanevsky AS, Wu H, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med. 2008;6:80.
84. Muthu MS, Singh S. Targeted nanomedicines: Effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine Lond. 2009;4:105-118.
85. Tang M, Xing T, Zeng J, et al. Unmodified CdSe quantum dots induce elevation of cytoplasmic calcium levels and impairment of functional properties of sodium channels in rat primary cultured hippocampal neurons. Environ Health Perspect. 2008;116:915-922.
86. Tang J, Xiong L, Wang S, Wang J, Liu L, Li J, Yuan F, Xi T. Distribution, translocation and accumulation of silver nanoparticles in rats. J Nanosci Nanotechnol. 2009;9:4924-4932.
87. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neuroscience Letters. 2006;406:189-193.
88. Bosi S, Da RT, Spalluto G, Balzarini J, Prato M. Synthesis and Anti-HIV properties of new water-soluble bis-functionalized [60]fullerene derivatives. Bioorg Med Chem Lett. 2003;13:4437-4440.
89. Niu J, Azfer A, Rogers LM, Wang X, Kolattukudy PE. Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardiovasc Res. 2007;73(3):549-559.
90. Crivori P, Cruciani G, Carrupt PA, Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem. 2000;43:2204-2216.
91. Madrid Y, Langer LF, Brem H, Langer R. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol. 1991;22:299-324.
92. Lambert DM. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci. 2000;11:15-27.
93. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci. 2000;2:6.
94. Bodor N, Buchwald P. Drug targeting via retrometabolic approaches. Pharmacol Ther. 1997;76:1-27.
95. Somogyi G, Nishitani S, Nomi D, Buchwald P, Prokai L, Bodor N. Targeted drug delivery to the brain via phosphonate derivatives. I: Design, synthesis, and evaluation of an anionic chemical delivery system for testosterone. Int J Pharm. 1998;166:15-26.
96. Bergley DJ. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol. 1996;48:136-146.
97. Banks WA, Audus KL, Davis TP. Permeability of the blood-brain barrier to peptides: An approach to the development of therapeutically useful analogs. Peptides. 1992;13:1289-1294.
98. Kusumi A, Koyama-Honda I, Suzuki K. Molecular dynamics and interactions for creation of stimulation-induced stabilized rafts from small unstable steady-state rafts. Traffic. 2004;5:213-230.
99. Anderson R, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science. 2002;296:1821-1825.
100. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet. 2007: Spec no. 2: R183-194.
101. Goetz CG. The history of Parkinson's disease: Early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1(1):a008862.
102. Maguire-Zeiss KA. ?-Synuclein: A therapeutic target for Parkinson's disease? Pharmaco Res. 2008; 58:271-280.
103. Auluck PK, Caraveo G, Lindquist S. ?-Synuclein: Membrane interactions and toxicity in Parkinson's disease. Ann Rev Cell Dev Biol. 2010; 26:211-233.
104. DeSantisME, Dersh D. Preventing Parkinson's pathology. DisModel Mech. 2010; 3:399-400.
105. Scott D, Taberean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in ?-synuclein-induced neurodegeneration. J Neurosci. 2010; 30(24):8083-8095.
106. Sheikh IA, Ali R, Dar TA, Kamal MA. An overview on potential neuroprotective compounds for management of Alzheimer's disease. CNS & Neurological Disorders-Drug Targets. 2012;11:1006-1011.
107. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Effectiveness of the Mediterranean diet: Can it help delay or prevent Alzheimer's disease. J Alzheimers Dis. 2010; 20:795-810.
108. Beard JL, Connor JR, Jones BC. Iron in the brain. Nutr Rev. 1993;51:157-170.
109. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith ME, Martins RN. Amyloid-beta: A chameleon walking in two worlds: A review of the trophic and toxic properties of amyloid-beta. Brain Res Rev. 2003; 43(1):1-16.
110. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci. 2001;98:12754-12759.
111. Gerard C, Bordeleau LJ, Barralet J, Doillon CJ. The stimulation of angiogenesis and collagen deposition by copper. Biomaterials. 2010;31:824-831.
112. Barralet J, Gbureck U, Habibovic P, Vorndran E, Gerard C, Doillon CJ. Angiogenesis in calcium phosphate scaffolds by metallic copper ion release. Tissue Eng Part A. 2009;15:1601-1609.
113. Taylor A. Therapeutic uses of trace elements. Clin Endocrinol Metab. 1985;14: 703-724.
114. Thompson KH, Orvig C. Boon and bane of metal ions in medicine. Science. 2003;300:936-939.
115. Cadosch D, Chan E, Gautschi OP, Filgueira L. Metal is not inert: Role of metal ions released by biocorrosion in aseptic loosening: current concepts. J Biomed Mater Res A. 2009;91:1252-1262.
116. Huber M, Reinisch G, Trettenhahn G, Zweymüller K, Lintner F. Presence of corrosion products and hypersensitivity-associated reactions in periprosthetic tissue after aseptic loosening of total hip replacements with metal bearing surfaces. Acta Biomater. 2009;5:172-180.
117. Guindy JS, Schiel H, Schmidli F, Wirz J. Corrosion at the marginal gap of implant-supported suprastructures and implant failure. Int J Oral Maxillofac Implants. 2004;19:826-831.
118. Kaida T, Kobayashi K, Adachi M, Suzuki F. Optical characteristics of titanium oxide interference film and the film laminated with oxides and their applications for cosmetics. J Cosmet Sci. 2004;55:219-220.
119. Adams LK, Lyon DY,McIntosh A, Alvarez PJ. Comparative toxicity of nano-scale TiO2, SiO2 and ZnO water suspensions. Water Sci Technol. 2006;54:327-334.
120. Warheit DB, Webb TR, Sayes CM, Colvin VL, Reed KL. Pulmonary instillation studies with nanoscale TiO2 rods and dots in rats: Toxicity is not dependent upon particle size and surface area. Toxicol Sci. 2006;91:227-236.
121. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, Oberdorster G, Ziesenis A. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A. 2002;65:1513-1530.
122. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles potential implications for drug delivery. J Nanosci Nanotechno. 2004;4:521-531.
123. Sonaje K, Lin KJ, Tseng MT, Wey SP, Su FY, Chuang EY, Hsu CW, Chen CT, Sung HW. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials. 2011;32(33):8712-8721.
124. Wu XF, Block ML, Zhang W, Qin L, Wilson B, Zhang WQ, Veronesi B, Hong JS. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal. 2005; 7(5-6):654-661.
125. Mattson MP. Mechanisms of neuronal apoptosis and excitotoxicity. Pathogenesis of neurodegenerative disorders. Contemporary neuroscience. 2001:1-20.
126. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon derived cells. Brain Res. 2000; 866(1-2):33-43.
127. Maier WE, Kodavanti PR, Harry GJ, Tilson HA. Sensitivity of adenosine triphosphatases in different brain regions to polychlorinated biphenyl congeners. J Appl Toxicol. 1994; 143(3):225-229.
128. Bickel U, Kang YS, Yoshikawa T, Pardridge WM. In vivo demonstration of subcellular localization of antitransferrin receptor monoclonal antibody colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem. 1994; 42:1493-1497.
129. Iijima S, Ichihashi T. Single-shell carbon nanotubes of 1 nm diameter. Nature. 1993;363:603-605.
130. Malarkey EB, Parpura V. Applications of carbon nanotubes in neurobiology. Neuro-Degenerative Diseases. 2007;4:292-299.
131. Gabay T, Jakobs E, Ben-Jacob E, Hanein Y. Engineered self-organization of neural networks using CNT clusters. Physica A. 2005;350:611-621.
132. McKnight TE, Melechko AV, Fletcher BL, Jones SW, Hensley DK, Peckys DB, Griffin GD, Simpson ML, Ericson MN. Resident neuroelectrochemical interfacing using carbon nanofiber arrays. J Phys Chem B. 2006;110:15317-15327.
133. Nguyen-Vu TD, Chen H, Cassell AM, Andrews R, Meyyappan M, Li J. Vertically aligned carbon nanofiber arrays: An advance toward electrical-neural interfaces. Small. 2006;2:89-94.
134. Nguyen-Vu TD, Chen H, Cassell AM, Andrews RJ, Meyyappan M, Li J. Vertically aligned carbon nanofiber architecture as a multi-functional 3-D neural electrical interface. IEEE Trans Biomed Eng. 2007;4:1121-1128.
135. Yu Z, McKnight TE, Ericson MN, Melechko AV, Simpson ML, Morrison B 3rd. Vertically aligned carbon nanofiber arrays record electrophysiological signals from hippocampal slices. Nano Lett. 2007; 7(8):2188-2195.
136. Wang K, Fishman HA, Dai H, Harris JS. Neural stimulation with a carbon nanotube microelectrode array. Nano Lett. 2006;6:2043-2048.
137. Service RF. Nanotechnology: Sorting technique may boost nanotube research. Science. 2003;300:2018.
138. Service RF. Nanotoxicology. Nanotechnology grows up. Science. 2004;304: 1732-1734.
139. Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. Nanotechnological approach towards anticancer research. Int J NanoMed. 2012;7: 4391-4408.
140. Buzea C, Blandino PII, Robbie K. Nanomaterials and NPs: Sources and toxicity. Biointerphases. 2007;2:MR17-MR71.
141. Batool S, Nawaz MS, Kamal MA. In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid. Investigational New Drugs. 2013; DOI 10.1007/s10637-013-9944- 9. (http://link.springer.com/article/10.1007/s10637-013-9944-9).
142. Tabrez S, Priyadarshini M, Urooj M, Shakil S, Ashraf GM, Khan MS, Kamal MA, Alam Q, Jabir NR, Abuzenadah AM, Chaudhary AGA, Damanhouri GA. Cancer chemoprevention by polyphenols and their potential application as nanomedicine. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013; 31(1):67-98. http://www.tandfonline.com/doi/full/10.1080/10590501.2013.763577.
143. Alam Q, Haque A, Alam MZ, Karim S, Kamal MA, Jiman-Fatani A, Damanhouri GA, Abuzenadah AM, Chaudhary AGA. Nanotechnological approach in management of Alzheimer's diseases and type 2 diabetes. CNS & Neurological Disorders-Drug Targets. 2013; (in press).